ST人福：注射用米卡芬净钠获得美国FDA批准文号

Core Viewpoint - ST Renfu's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received approval from the U.S. Food and Drug Administration (FDA) for Micafungin Sodium for injection, which is indicated for the treatment of candidemia, acute disseminated candidiasis, candidal peritonitis, and abscesses in adults and pediatric patients aged 4 months and older [1] Summary by Category Product Approval - The FDA approval allows Yichang Renfu to market Micafungin Sodium in the U.S. [1] - The drug is approved for use in both adult and pediatric patients [1] Financial Investment - The total research and development investment for this project amounts to approximately RMB 6.8 million [1] Market Potential - According to IQVIA data, the annual sales for Micafungin Sodium in the U.S. market are projected to be around USD 67 million in 2024 [1]